Krystal Biotech, Inc. (KRYS) Income Statement
KRYS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsKRYS revenue and net income
Where KRYS's revenue goes
2025Each bar shows an amount and its share of revenue. KRYS kept 52.6% of revenue as net income.
KRYS profit margins
KRYS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +33.9% | — | — | — |
| Gross profit | +33.2% | — | — | — |
| Operating income | +145.5% | — | — | — |
| Net income | +129.7% | — | — | — |
| EPS (diluted) | +101.5% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KRYS quarterly EPS vs estimates
Krystal Biotech beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 2, 2026 (estimate $1.88).
KRYS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $389.1M | $290.5M | $50.7M | $0 | $0 | $0 | $0 | $1.0M | $0 | $0 |
| Cost of revenue | $28.8M | $20.1M | $3.1M | $4.1M | $2.8M | $1.9M | $974,000 | $141,000 | $23,000 | $2,000 |
| Gross profit | $360.4M | $270.5M | $47.6M | −$4.1M | −$2.8M | −$1.9M | −$974,000 | $886,000 | −$23,000 | −$2,000 |
| Research & development | $58.0M | $53.6M | $46.4M | $42.5M | $27.9M | $17.9M | $15.6M | $7.8M | $3.2M | $741,000 |
| Sales, general & admin | $146.7M | $113.7M | $98.4M | $77.7M | $40.4M | $15.1M | $6.5M | $4.2M | $1.6M | $402,000 |
| Total operating expenses | $199.1M | $204.8M | $157.3M | $145.2M | $68.3M | $31.1M | $22.1M | $11.9M | $4.8M | $1.1M |
| Operating income | $161.3M | $65.7M | −$109.7M | −$145.2M | −$68.3M | −$33.0M | −$22.1M | −$11.9M | −$4.8M | −$1.1M |
| Interest income | $28.2M | $29.7M | $22.6M | $5.2M | $197,000 | $832,000 | $3.0M | $1.0M | $3.1M | $7,000 |
| Interest expense | — | — | $0 | $5.2M | $1.5M | $832,000 | $0 | $1.0M | $3.1M | $7,000 |
| Income before taxes | $189.5M | $95.4M | $12.9M | −$140.0M | −$69.6M | −$32.2M | −$19.1M | −$10.9M | −$7.9M | −$1.1M |
| Income taxes | −$15.4M | $6.2M | $2.0M | $34.0M | $2.7M | $1.6M | $576,140 | −$20,141 | $0 | $0 |
| Net income | $204.8M | $89.2M | $10.9M | −$140.0M | −$69.6M | −$32.2M | −$19.1M | −$10.9M | −$7.9M | −$1.1M |
| EBITDA | $196.0M | $109.9M | −$92.2M | −$116.1M | −$65.3M | −$30.3M | −$18.1M | −$10.7M | −$4.6M | −$1.1M |
| EPS (diluted) | $6.85 | $3.40 | −$2.72 | −$4.51 | −$3.13 | −$1.70 | −$1.22 | −$0.96 | −$1.58 | −$0.27 |
| Gross margin | 92.6% | 93.1% | 93.9% | — | — | — | — | 86.3% | — | — |
| Operating margin | 41.5% | 22.6% | −216.4% | — | — | — | — | −1,160.3% | — | — |
| Net margin | 52.6% | 30.7% | 21.6% | — | — | — | — | −1,060.3% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $119.2M | $116.4M | $107.1M | $97.8M | $96.0M | $88.2M | $91.1M | $83.8M | $70.3M | $45.2M | $42.1M | $8.6M |
| Cost of revenue | $6.4M | $6.3M | $10.9M | $5.7M | $7.2M | $5.0M | $4.9M | $6.7M | $6.0M | $2.4M | $4.4M | $223,000 |
| Gross profit | $112.8M | $110.0M | $96.2M | $92.1M | $88.9M | $83.2M | $86.2M | $77.2M | $64.3M | $42.8M | $37.8M | $8.3M |
| Research & development | $14.5M | $15.3M | $16.2M | $13.2M | $14.4M | $14.3M | $13.5M | $13.5M | $15.6M | $11.0M | $11.4M | $10.6M |
| Sales, general & admin | $39.9M | $41.0M | $41.4M | $37.6M | $35.2M | $32.7M | $31.3M | $28.7M | $27.6M | $26.1M | $73.6M | $23.7M |
| Total operating expenses | $54.4M | $56.3M | $51.8M | $50.8M | $49.6M | $47.0M | $44.8M | $54.7M | $55.7M | $49.5M | $34.6M | $34.3M |
| Operating income | $58.4M | $53.7M | $44.4M | $41.4M | $39.3M | $36.2M | $41.4M | $22.4M | $8.6M | −$6.7M | $3.1M | −$26.0M |
| Interest income | $7.7M | — | $6.9M | $6.6M | $7.5M | — | — | $7.3M | $7.5M | $7.6M | $7.5M | $6.7M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $25.0M | — |
| Income before taxes | $66.1M | $61.4M | $51.1M | $48.0M | $46.8M | $43.6M | $48.6M | $29.8M | $16.0M | $932,000 | $10.7M | $80.7M |
| Income taxes | $11.3M | $5.5M | −$268,000 | −$31.4M | $8.4M | $7.9M | $3.1M | $2.6M | $477,000 | $4.9M | $2.0M | −$826,000 |
| Net income | $54.8M | $55.9M | $51.4M | $79.4M | $38.3M | $35.7M | $45.5M | $27.2M | $15.6M | $932,000 | $8.7M | $80.7M |
| EBITDA | $67.6M | $63.2M | $39.6M | $49.6M | $48.3M | $45.2M | $50.2M | $36.5M | $23.1M | $7.4M | $12.2M | $82.1M |
| EPS (diluted) | $1.79 | $1.83 | $1.70 | $2.66 | $1.29 | $1.20 | $1.53 | $0.91 | $0.93 | $0.03 | $0.96 | −$0.67 |
| Gross margin | 94.6% | 94.6% | 89.8% | 94.2% | 92.5% | 94.3% | 94.6% | 92.0% | 91.5% | 94.7% | 89.6% | 97.4% |
| Operating margin | 49.0% | 46.1% | 41.5% | 42.3% | 40.9% | 41.0% | 45.4% | 26.8% | 12.2% | −14.8% | 7.4% | −303.8% |
| Net margin | 45.9% | 48.1% | 48.0% | 81.2% | 39.9% | 40.5% | 49.9% | 32.4% | 22.2% | 2.1% | 20.6% | 943.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KRYS's financial statements (latest annual report filed February 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KRYS financial results
In fiscal year 2025 (ended December 31, 2025), Krystal Biotech reported revenue of $389.1 million, up 33.9% from the year before. It had net income of $204.8 million (up 129.7%), a net profit margin of 52.6%. Diluted earnings per share came to $6.85.
See the KRYS stock overview for the latest quote and news, or the KRYS chart for price history and technical indicators.
KRYS income statement FAQ
What is Krystal Biotech's annual revenue?
Krystal Biotech reported total revenue of $389.1 million for fiscal year 2025, which ended on December 31, 2025. That was up 33.9% from $290.5 million the previous year.
Is Krystal Biotech profitable?
Yes. Krystal Biotech reported net income of $204.8 million in fiscal 2025, a net profit margin of 52.6%; its operating margin was 41.5%.
What is Krystal Biotech's gross margin?
Krystal Biotech's gross margin was 92.6% in fiscal 2025: for every $100 of revenue, Krystal Biotech kept $93 after the direct cost of its products and services.
How much does Krystal Biotech spend on research and development?
Krystal Biotech spent $58.0 million on research and development in fiscal 2025, 14.9% of revenue.
What are Krystal Biotech's earnings per share?
Krystal Biotech earned $6.85 per diluted share in fiscal 2025, compared with $3.40 a year earlier.
When will Krystal Biotech report its next earnings?
Krystal Biotech is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 before the market opens.
When does Krystal Biotech's fiscal year end?
Krystal Biotech's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 17, 2026.